– Announced Today the Resubmission to the FDA of the NDA for YOSPRALA™-

– Expects 2016 Net Revenues to be in a Range of $48 Million to $58 Million-

MILTON, Ontario, March 15, 2016 /CNW/ — Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (“Aralez” or the…